SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.85
+0.73%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.74
From 52W high−32.34%
Volume12.96M
Market cap$14.24B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$17.74
From 52W high
−32.34%
Volume
12.96M
Market cap
$14.24B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.9x
P/E (TTM)
—
RSI (14)
62.0
MomentumView details →
1D Return
+0.73%
YTD Return
+0.35%
SummaryUpdated Jun 1, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.
Similar companies
Latest newsMore news →
Summit Therapeutics presented updated overall survival results from the global Phase III HARMONi clinical trial of ivonescimab plus chemotherapy in Western and Asian patients at WCLC 2026 in Seoul, Republic of Korea.5d agoSummit Therapeutics stock jumped 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.16d agoAkeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.18d ago